Aclaris therapeutics announces formation of new scientific advisory board

Wayne, pa., jan. 30, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new scientific advisory board (sab), which initially includes experts in the field of pulmonology. these include marianne mann, m.d.
ACRS Ratings Summary
ACRS Quant Ranking